Dr. Erich Tauber
Chief Executive Officer, Co-Founder
Erich Tauber is co-founder and CEO of Themis since its inception.
He has joined the Pharmaceutical and Biotech Industry in 2000, and served in roles with increasing responsibilities in AstraZeneca, Baxter, Intercell and Nycomed. He is an expert in vaccine development, and has substantial experience in the clinical and regulatory field.
He received academic training at the University of Vienna, University of Southampton, WU Executive Academy Vienna, and received his habilitation for Clinical Pharmacology at the Medical University of Vienna. Before joining the industry, he received medical training as a Pediatrician.
Dr. David A. Maier
Chief Financial Officer
Dr. Gerd Zettlmeissl
Gerd Zettlmeissl has been working in various R&D and General Management positions in the biopharmaceutical and vaccine industry since 1985.
His last positions were Managing Director of Chiron Behring, a leading vaccine manufacturer in Germany, and until May 2011, Chief Executive Officer of Intercell, in Austria. During his career, he made major contributions to the discovery, development and registration of a number of biologicals and vaccines.
He currently serves as Non-Executive Director of Aeras, a non-profit organization developing tuberculosis vaccines, and of various biotech companies. Gerd is holding a doctoral degree in biochemistry of the University of Regensburg and did a post-doctoral fellowship at the Institut Pasteur Paris in virology between 1983 and 1985.
Dr. Philippe Dro
In the last 20 years Philippe Dro initiated and executed several strategic transactions. Prior to its acquisition by GSK, he served at the vaccine developer GlycoVaxyn AG as CEO and member of the Supervisory Board.
Before that, he led EndoArt S.A., a medtech company, in the position of CEO and Chairman of the Board through a successful sale process of the company to Allergan. When Actelion acquired Axovan AG, he was acting CFO and Head of Business Development.
Prior to that, he served at Novartis, Skyepharma and Antares Pharma in a number of responsible functions.
Dr. Mounia Chaoui
Mounia Chaoui is Venture Partner at Ventech and General partner at Turenne capital in charge of Venture and Growth Capital in healthcare totaling 110 Mio EUR since 2013.
Prior to this, Mounia has been a Life Science investor within Ventech (since 2001), Inserm Transfert Initiative (2012) and Atlas Venture (1998 to 1999). She has been on the board of Actogenix (sold to Intrexon), Biovex (sold to Amgen for up to 1 billion USD), Covagen (sold toJ&J), EyeGate (now EYGT), Funxional Therapeutics (sold to Boehringer Ingelheim), Prosonix (sold to Circassia), T Igenix (now EUR:TIG) and SCYNEXIS (SCYX).
Besides Themis, Mounia is on the board of Alize Pharma, Didactic, DNA therapeutics, EyeGate, EYETECHCARE, JRI and SEBBIN. Mounia holds a PhD in Biophysics and an Engineering degree from Ecole Centrale Paris.
Dr. Bruno Montanari
Bruno Montanari is a Partner at Omnes Capital, where he joined the VC team in January 2010.
He began his career in 1999 in London as an Investment Banker in the Healthcare Groups of Deutsche Bank and Meryll Lynch, before joining the venture capital community first with CDP Capital, and later Atlas Venture in 2004, where he was a Pricipal in the Life Science Group.
Bruno holds a PharmD from the Université René Descartes Paris V and a Masters Degree in Strategic Management from HEC Paris, France.
Dr. Regina Hodits
Regina Hodits is a General Partner at Wellington Partners and represents the Wellington funds on the Boards of Themis, Rigontec, Middle Peak Medical, AYOXXA, and Atopix. She was a founding investor in Sapiens, which was sold to Medtronic, and an external director at GlaxoSmithKline's Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences.
Further stations of her career were Atlas Venture and Apax Partners, for which she served on several Boards, including Bicycle Therapeutics, F-star (partly acquired by BMS), U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), Egalet (NASDAQ: EGLT), and Novamed, (acquired by SciClone, NASDAQ SCLN).
Regina Hodits studied chemical engineering in Vienna and holds a Ph.D. in biochemistry. She started to build her extensive network in the global healthcare industry during her tenure at McKinsey.
Dr. Jean Paul Prieels
After ten years at academia, Jean Paul Prieels started his industrial career at Petrofina in 1983 as Biotechnology Manager and joined GlaxoSmithKline Biologicals in 1987. His responsibilities gradually expanded to lead the vaccine preclinical R&D development activities in Rixensart, Belgium. He retired as Senior Vice President of Research & Development at GlaxoSmithKline Biologicals in 2011.
His career spans from basic research to applied research and product development. He was instrumental in the development of several commercially available vaccines, such as Rotarix, Cervarix and Synflorix.
Today he is involved as director or member of the advisory board in biotechs and non-profit organizations. Jean Paul Prieels holds a PhD in Biochemistry from Université Libre de Bruxelles, Belgium.
Ralf Kunzmann is Managing Director of aws Fondsmanagement GmbH and aws Founders Fund (aws Gründerfonds), Austria’s most active Venture Capital Fund. Before joining aws in 2013 he was many years responsible for the international private equity activities of UniCredit Bank Austria Group and held numerous operational management functions as Managing Director and CFO at portfolio companies.
Prior to that, he worked with KPMG in financial advisory services with specialization in corporate finance. After completing his studies in business administration, Ralf started his career in the healthcare industry in Investment Controlling and Corporate Development.
Ralf is lecturer and author of numerous publications in the field of business acquisition.
Scientific Advisory Board
Dr. Christian Mandl
Christian Mandl previously served as Global Head of Novartis Vaccines' Research and Early/Exploratory Clinical Development.
In this role, he directed a team of 300 scientists working on over 15 viral and bacterial vaccine pipeline projects and platform technologies.
Prior to Novartis, he acted as Professor and Deputy Head of the Department of Virology at the Medical University of Vienna.
He is an internationally renowned expert on flaviviruses and co-inventor on several patents related to the marketed vaccine against tick-borne encephalitis.